2.53
-0.04 (-1.37%)
| Penutupan Terdahulu | 2.56 |
| Jumlah Dagangan | 272,488 |
| Harga / Buku (P/B) | 9.93 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -3.97 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 65.04% |
| Nisbah Semasa (MRQ) | 1.83 |
| Aliran Tunai Operasi (OCF TTM) | -35.06 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -20.96 M |
| Pulangan Atas Aset (ROA TTM) | -108.03% |
| Pulangan Atas Ekuiti (ROE TTM) | -744.59% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Elicio Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.36 |
|
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 43.87% |
| % Dimiliki oleh Institusi | 10.26% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Knoll Capital Management, Llc | 30 Jun 2026 | 1,211,957 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |